News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria



6/17/2014 10:11:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The grant supports the research by Selecta for a novel dual action, immune-activating Synthetic Vaccine Particle (SVP) for malaria. (instead of The grant supports the research by Selecta for a novel dual action, immune-activating SVP (SVP) nanoparticle vaccine for malaria.)

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   
Malaria
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES